Effect of Intracameral Moxifloxacin 0.5% Ophthalmic Solution on Corneal Endothelium in Cataract Patients with Penetrating Keratoplasty

1
Effect of Intracameral Moxifloxacin 0.5
Ophthalmic Solution on Corneal Endothelium in
Cataract Patients with Penetrating Keratoplasty

• Osman Sevki Arslan, Mustafa Ilker Toker, N. Melda
  Yenerel, Ebru Gorgun
• Department of Ophthalmology,
• Istanbul University Cerrahpasa Medical School,
  Istanbul, TURKEY
• The authors have no financial interest in the
  subject matter of this poster

2
Aim

• The aim of this study was to evaluate effect of
  prophylactic intracameral moxifloxacin 0.5
  ophthalmic solution (Vigamox) on corneal
  endothelial cells in cataract surgery patients
  with penetrating keratoplasty

3
Methods

• Thirty eyes of 30 cataract patients with
  penetrating keratoplasty(PK) were included the
  study.
• PK surgeries of the patients were applied minimum
  2 months and maximum 4.5 years before the
  cataract surgeries.
• Phacoemulsification surgery was performed to the
  all patients as cataract surgery.

4
Methods

• Preoperative and 1 week, 1 month and 3 months
  postoperative central corneal thickness(CCT) and
  corneal endothelial cell density(CECD) were
  measured.
• 0.05 mL intracameral moxifloxacin 0.5 ophthalmic
  solution (Vigamox) containing 500 mg of
  moxifloxacin was given to the all eyes as the
  last step of phacoemulsification.

5
Methods

• Postoperative antibiotics included topical
  Vigamox every 2 hours while awake on the day of
  the surgery. The Vigamox was reduced to 4 times a
  day until the bottle was empty.

6
Results

• All 30 eyes of 30 patients completed the study.
• There were not statistically significant
  difference between preoperative and postoperative
  CCT and CECD values of the patients (Pgt0.05).
• There were no infections in any cases.

7
Conclusion

• Prophylactic intracameral moxifloxacin 0.5
  ophthalmic solution did not significantly affect
  the corneal endothelial cells of cataract surgery
  patients with PK in 3 months follow-up period.

8
Conclusion

• Although this patients group is small and there
  is a need to wide and long term studies, we can
  say intracameral moxifloxacin 0.5 mg/mL was safe
  to use in infection prophylaxis in cataract
  surgery patients with PK.